Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0UT4W
|
|||
| Drug Name |
Zanubrutinib
|
|||
| Synonyms |
RNOAOAWBMHREKO-UHFFFAOYSA-N; 1633350-06-7; ( inverted exclamation markA)-Zanubrutinib; CHEMBL3973435; SCHEMBL19742851; SCHEMBL16208602; BGB3111; BDBM249900; BCP29110; BCP25045; BCP25838; AKOS032946689; SB18877; CS-6366; ( inverted exclamation markA)-BGB-3111; HY-101474; US9447106, 27
Click to Show/Hide
|
|||
| Indication | Mantle cell lymphoma [ICD-11: 2A85.5; ICD-10: C83.1] | Approved | [1] | |
| Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 3 | [2] | ||
| Small lymphocytic lymphoma [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 3 | [2] | ||
| Waldenstrom macroglobulinemia [ICD-11: 2A85.4; ICD-10: C88.0; ICD-9: 273.3] | Phase 3 | [2] | ||
| B-cell lymphoma [ICD-11: 2A86; ICD-10: C85.1; ICD-9: 202.8] | Phase 1 | [2] | ||
| Company |
BeiGene Cambridge, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H29N5O3
|
|||
| Canonical SMILES |
C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N
|
|||
| InChI |
1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)
|
|||
| InChIKey |
RNOAOAWBMHREKO-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.